Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICT-01: Neoadjuvant Pembrolizumab in High-Risk Prostate Cancer
NCT04009967Phase 2Active, not recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- Jan 2020
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in prostate cancer (PCa), sponsored by CHU de Québec-Université Laval. Started Jan 2020; status: active, not recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04009967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009967.